222 related articles for article (PubMed ID: 25366911)
21. Development of a Mitochondrial Targeting Lipid Nanoparticle Encapsulating Berberine.
Hori I; Harashima H; Yamada Y
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674418
[TBL] [Abstract][Full Text] [Related]
22. Validation of a Strategy for Cancer Therapy: Delivering Aminoglycoside Drugs to Mitochondria in HeLa Cells.
Abe J; Yamada Y; Harashima H
J Pharm Sci; 2016 Feb; 105(2):734-740. PubMed ID: 26523487
[TBL] [Abstract][Full Text] [Related]
23. The use of a MITO-Porter to deliver exogenous therapeutic RNA to a mitochondrial disease's cell with a A1555G mutation in the mitochondrial 12S rRNA gene results in an increase in mitochondrial respiratory activity.
Yamada Y; Maruyama M; Kita T; Usami SI; Kitajiri SI; Harashima H
Mitochondrion; 2020 Nov; 55():134-144. PubMed ID: 33035688
[TBL] [Abstract][Full Text] [Related]
24. The Use of a Microfluidic Device to Encapsulate a Poorly Water-Soluble Drug CoQ
Hibino M; Yamada Y; Fujishita N; Sato Y; Maeki M; Tokeshi M; Harashima H
J Pharm Sci; 2019 Aug; 108(8):2668-2676. PubMed ID: 30959057
[TBL] [Abstract][Full Text] [Related]
25. Targeted mitochondrial delivery of antisense RNA-containing nanoparticles by a MITO-Porter for safe and efficient mitochondrial gene silencing.
Kawamura E; Hibino M; Harashima H; Yamada Y
Mitochondrion; 2019 Nov; 49():178-188. PubMed ID: 31472283
[TBL] [Abstract][Full Text] [Related]
26. Packaging of the Coenzyme Q
Yamada Y; Burger L; Kawamura E; Harashima H
Biol Pharm Bull; 2017; 40(12):2183-2190. PubMed ID: 29199241
[TBL] [Abstract][Full Text] [Related]
27. Mitochondrial delivery of antisense RNA by MITO-Porter results in mitochondrial RNA knockdown, and has a functional impact on mitochondria.
Furukawa R; Yamada Y; Kawamura E; Harashima H
Biomaterials; 2015 Jul; 57():107-15. PubMed ID: 25913255
[TBL] [Abstract][Full Text] [Related]
28. A synthetic mitochondrial-based vector for therapeutic purposes.
Renteln M
Med Hypotheses; 2018 Aug; 117():28-30. PubMed ID: 30077190
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial transgene expression via an artificial mitochondrial DNA vector in cells from a patient with a mitochondrial disease.
Ishikawa T; Somiya K; Munechika R; Harashima H; Yamada Y
J Control Release; 2018 Mar; 274():109-117. PubMed ID: 29408532
[TBL] [Abstract][Full Text] [Related]
30. [A Nanocarrier System for Mitochondrial Delivery Targeted to a Pancreatic Beta Cell].
Yamada Y
Yakugaku Zasshi; 2019; 139(1):41-45. PubMed ID: 30606927
[TBL] [Abstract][Full Text] [Related]
31. Validation of Gene Therapy for Mutant Mitochondria by Delivering Mitochondrial RNA Using a MITO-Porter.
Kawamura E; Maruyama M; Abe J; Sudo A; Takeda A; Takada S; Yokota T; Kinugawa S; Harashima H; Yamada Y
Mol Ther Nucleic Acids; 2020 Jun; 20():687-698. PubMed ID: 32388194
[TBL] [Abstract][Full Text] [Related]
32. Investigation of the Nanoparticulation Method and Cell-Killing Effect following the Mitochondrial Delivery of Hydrophobic Porphyrin-Based Photosensitizers.
Naganawa R; Zhao H; Takano Y; Maeki M; Tokeshi M; Harashima H; Yamada Y
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673875
[TBL] [Abstract][Full Text] [Related]
33. Validation of the Mitochondrial Delivery of Vitamin B
Yamada Y; Ishimaru T; Ikeda K; Harashima H
J Pharm Sci; 2022 Feb; 111(2):432-439. PubMed ID: 34478755
[TBL] [Abstract][Full Text] [Related]
34. Activation of Mitochondrial Oxygen Consumption Rate by Delivering Coenzyme Q
Sato I; Hibino M; Takeda A; Harashima H; Yamada Y
J Pharm Sci; 2024 Jul; 113(7):1836-1843. PubMed ID: 38325738
[TBL] [Abstract][Full Text] [Related]
35. Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.
Yamada Y; Somiya K; Miyauchi A; Osaka H; Harashima H
Sci Rep; 2020 May; 10(1):7511. PubMed ID: 32371897
[TBL] [Abstract][Full Text] [Related]
36. A mitochondrial delivery system using liposome-based nanocarriers that target myoblast cells.
Katayama T; Kinugawa S; Takada S; Furihata T; Fukushima A; Yokota T; Anzai T; Hibino M; Harashima H; Yamada Y
Mitochondrion; 2019 Nov; 49():66-72. PubMed ID: 31326598
[TBL] [Abstract][Full Text] [Related]
37. Human cardiosphere-derived cells with activated mitochondria for better myocardial regenerative therapy.
Shiraishi M; Sasaki D; Hibino M; Takeda A; Harashima H; Yamada Y
J Control Release; 2024 Mar; 367():486-499. PubMed ID: 38295995
[TBL] [Abstract][Full Text] [Related]
38. RNA Delivery to Mitochondria.
Yamada Y; Harashima H
Handb Exp Pharmacol; 2024; 284():329-339. PubMed ID: 37017791
[TBL] [Abstract][Full Text] [Related]
39. Innovative cancer nanomedicine based on immunology, gene editing, intracellular trafficking control.
Yamada Y; Sato Y; Nakamura T; Harashima H
J Control Release; 2022 Aug; 348():357-369. PubMed ID: 35623492
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Strategies for Regulating Mitochondrial Oxidative Stress.
Yamada Y; Takano Y; Satrialdi ; Abe J; Hibino M; Harashima H
Biomolecules; 2020 Jan; 10(1):. PubMed ID: 31948035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
